Cooley, Linklaters Steer Biopharma Genfit's $135M Debut
French biopharmaceutical company Genfit SA began trading in the U.S. Wednesday after picking up $135.1 million through an initial public offering and private placement that the Cooley LLP and Linklaters LLP-led...To view the full article, register now.
Already a subscriber? Click here to view full article